Menu Search
Equities

Medicamen Organics Ltd

MEDIORG:NSI

Medicamen Organics Ltd

Actions
  • Price (INR)66.00
  • Today's Change2.00 / 3.13%
  • Shares traded8.00k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 10:56 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Medicamen Organics Ltd grew revenues 14.11% from 221.47m to 252.72m while net income improved 91.93% from 12.53m to 24.04m.
Gross margin42.12%
Net profit margin9.51%
Operating margin15.90%
Return on assets--
Return on equity--
Return on investment--
More ▼

Cash flow in INRView more

In 2024, Medicamen Organics Ltd did not generate a significant amount of cash. Cash Flow from Financing totalled 40.14m or 15.88% of revenues. In addition the company used 36.89m for operations while cash used for investing totalled 3.33m.
Cash flow per share2.67
Price/Cash flow per share24.72
Book value per share12.98
Tangible book value per share12.97
More ▼

Balance sheet in INRView more

Medicamen Organics Ltd has a Debt to Total Capital ratio of 45.46%.
Current ratio1.25
Quick ratio0.9695
Total debt/total equity0.8335
Total debt/total capital0.4546
More ▼

Growth rates in INR

Year on year, growth in earnings per share excluding extraordinary items increased 91.93%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		--
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.